This work is licensed under a Creative Commons Attribution 4.0 International License.
Sequence 39 from Patent US 20110159022
General Information
DRACP ID DRACP01346
Peptide Name Sequence 39 from Patent US 20110159022
Sequence LTLGEFLKL
Sequence Length 9
PubChem CID Not available
Origin Synthetic construct
Type Synthetic peptide
Classification
Active ACP
Activity Information
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Not available
Disulfide/Other Bond Not available
N-terminal Modification Not available
C-terminal Modification Not available
Other Modification None
Chiral L
Physicochemical Information
Formula C50H84N10O13
Absent amino acids ACDHIMNPQRSVWY
Common amino acids L
Mass 117616
Pl 6.41
Basic residues 1
Acidic residues 1
Hydrophobic residues 5
Net charge 0
Boman Index 867
Hydrophobicity 105.56
Aliphatic Index 173.33
Half Life
Mammalian: 5.5 hour
Yeast: 3 min
E.coli: 2 min
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 2
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US 2011/0159022 A1
Patent Title Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine.
Other Iinformation Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status: Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;
Other Published ID CA2728459A1 CN102123731A EP2296697A1 WO2009153463A1
This work is licensed under a Creative Commons Attribution 4.0 International License.